Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

40.46USD
20 Jan 2017
Change (% chg)

$0.06 (+0.15%)
Prev Close
$40.40
Open
$40.54
Day's High
$40.77
Day's Low
$40.35
Volume
2,565,839
Avg. Vol
2,442,408
52-wk High
$45.58
52-wk Low
$36.00

ABT.N

Chart for ABT.N

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $69,842.05
Shares Outstanding(Mil.): 1,726.20
Dividend: 0.26
Yield (%): 2.62

Financials

  ABT.N Industry Sector
P/E (TTM): 60.85 29.51 30.38
EPS (TTM): 0.66 -- --
ROI: 3.11 15.44 14.86
ROE: 4.74 16.62 16.28

BRIEF-Abbott announces European launch of the Proclaim DRG Neurostimulation system

* Abbott announces european launch of the Proclaim DRG neurostimulation system for the management of chronic neuropathic pain Source text for Eikon: Further company coverage:

Jan 18 2017

BRIEF-New Data confirms Abbott's dorsal root ganglion stimulation offers greater treatment success

* Abbott Laboratories - new data confirms Abbott's dorsal root ganglion stimulation offers greater treatment success over traditional spinal cord stimulation Source text for Eikon: Further company coverage:

Jan 17 2017

BRIEF-Biogaia's probiotic to be launched in Thailand

* Biogaia has signed an exclusive agreement with Abbott for the rights to commercialize Biogaia products in the area of paediatrics and gastroenterology in Thailand Further company coverage: (Reporting by Stockholm Newsroom)

Jan 13 2017

BRIEF-Abbott announces U.S. launch, first commercial use of new ensite precision cardiac mapping system

* Abbott announces u.s. Launch and first commercial use of the new ensite precision cardiac mapping system Source text for Eikon: Further company coverage:

Jan 12 2017

BRIEF-Abbott announces CE mark for its "Alinity s" blood and plasma screening system

* Abbott announces CE mark for its "Alinity s" blood and plasma screening system Source text for Eikon: Further company coverage:

Jan 10 2017

St. Jude releases cyber updates for heart devices after U.S. probe

Abbott Laboratories moved to protect patients with its St. Jude heart implants against possible cyber attacks, releasing a software patch on Monday that the firm said will reduce the "extremely low" chance of them being hacked.

Jan 09 2017

St. Jude releases cyber updates for heart devices after U.S. probe

Abbott Laboratories moved to protect patients with its St. Jude heart implants against possible cyber attacks, releasing a software patch on Monday that the firm said will reduce the "extremely low" chance of them being hacked.

Jan 09 2017

UPDATE 5-St. Jude releases cyber updates for heart devices after U.S. probe

Jan 9 Abbott Laboratories moved to protect patients with its St. Jude heart implants against possible cyber attacks, releasing a software patch on Monday that the firm said will reduce the "extremely low" chance of them being hacked.

Jan 09 2017

Abbott releases cyber updates for St. Jude devices after gov't probe

Jan 9 Abbott Laboratories said on Monday it is releasing cyber security updates for its St. Jude heart devices following a U.S. government investigation into claims the products are vulnerable to potentially life-threatening hacks.

Jan 09 2017

Abbott gets U.S. antitrust approval to buy St. Jude Medical

WASHINGTON Healthcare company Abbott Laboratories has won U.S. antitrust approval for its proposed $25 billion acquisition of medical device maker St. Jude Medical Inc , the U.S. Federal Trade Commission said on Tuesday. | Video

Dec 28 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $114.15 -0.05
Pfizer Inc. (PFE.N) $31.77 +0.07
Novartis AG (NOVN.S) CHF70.90 -0.20
Merck & Co., Inc. (MRK.N) $62.53 +2.20
Sanofi SA (SASY.PA) €75.62 -0.15
AstraZeneca plc (AZN.L) 4,318.50 -150.00
GlaxoSmithKline plc (GSK.L) 1,546.50 -6.50
Eli Lilly and Co (LLY.N) $76.81 -0.03
Amgen, Inc. (AMGN.OQ) $154.67 +0.87
Boston Scientific Corporation (BSX.N) $23.90 +0.02

Earnings vs. Estimates